Zobrazuji výsledky 1 - 5 z 5 pro vyhledávání 'Per Jynge', doba hledání: 0,03 s. Upřesnit hledání
  1. 1
    May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?

    May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Autor Jan Olof G Karlsson, Per Jynge, Louis J Ignarro

    Vydáno 2020-10-01
    Získat plný text
    Článek
  2. 2
    Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2+</sup>

    Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2+</sup> Autor Jan Olof G. Karlsson, Per Jynge, Louis J. Ignarro

    Vydáno 2023-03-01
    Získat plný text
    Článek
  3. 3
    Mangafodipir a Selective Cytoprotectant — with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)

    Mangafodipir a Selective Cytoprotectant — with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN) Autor Jan Olof G. Karlsson, Rolf GG Andersson, Per Jynge

    Vydáno 2017-08-01
    Získat plný text
    Článek
  4. 4
    The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx

    The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx Autor Jan Olof G. Karlsson, Per Jynge, Louis J. Ignarro

    Vydáno 2021-12-01
    Získat plný text
    Článek
  5. 5
    Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”

    Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for para... Autor Jan Olof G. Karlsson, Per Jynge, Ingemar Lundström, Louis J. Ignarro

    Vydáno 2019-06-01
    Získat plný text
    Článek

Vyhledávací nástroje: